Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs

Keyphrases

• Novel Therapeutics 100%
• Protein Kinase C Agonists 100%
• HIV Reservoir 100%
• Latent HIV-1 100%
• Natural Products 66%
• Molecular Mechanism 66%
• HIV Latency 66%
• HIV-1 Reactivation 66%
• Viral Reservoir 66%
• Purging 66%
• Latency 33%
• Human Immunodeficiency Virus Type 1 (HIV-1) 33%
• Pharmacological Manipulation 33%
• Promoter Activity 33%
• HIV Patients 33%
• Conventional Therapy 33%
• Therapeutic Potential 33%
• Transcriptional Activity 33%
• Polyester 33%
• Experimental Therapeutics 33%
• Polyclonal Activation 33%
• Therapeutic Agents 33%
• Potential Therapeutics 33%
• Infected Cells 33%
• Semi-synthetic 33%
• Molecular Targets 33%
• Latent Reservoir 33%
• Virus Removal 33%
• Prostratin 33%
• Latent HIV 33%
• Ingenol 33%
• Multiple Processes 33%
• Tumor Promoter 33%
• Jatrophane 33%
• Reactivation from Latency 33%
• Reactivation Therapy 33%
• HIV-1 Provirus 33%
• Highly Active Antiretroviral Therapy (HAART) 33%
• Macrolides 33%
• Integrated HIV 33%
• Cellular Reservoirs 33%
• Bryostatin 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Kinase C 100%
• HIV 100%
• Natural Product 18%
• Molecular Target 9%
• Viral Clearance 9%
• Ingenol 9%
• Macrolide 9%
• Bryostatin 1 9%
• Tumor Promoter 9%

Immunology and Microbiology

• Agonist 100%
• Human Immunodeficiency Virus 1 100%
• Promoter Region 10%
• Human Immunodeficiency Virus 10%
• Provirus 10%
• Bryostatin 1 10%
• Polyclonal Activation 10%
• Viral Clearance 10%